Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies

BACKGROUND: Eribulin mesylate is currently approved in the United States and Europe for the treatment of metastatic breast cancer (MBC). SCOPE: The objective of this retrospective study is to find specific predictive criteria related to patient or tumor characteristics in order to select patients th...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Drugs Context
Prif Awduron: Rossi, Sabrina, Cassano, Alessandra, Strippoli, Antonia, Schinzari, Giovanni, D’Argento, Ettore, Basso, Michele, Barone, Carlo
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioExcel Publishing Ltd 2017
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5699107/
https://ncbi.nlm.nih.gov/pubmed/29167692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212506
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg